MRNA vs ARGX stock comparison
Moderna vs. Argenx · data as of November 13, 2026
Moderna (MRNA) has a market value of about $90.4B, Argenx (ARGX) about $59.6B. Over their latest twelve months Moderna had revenue of $2.5B and Argenx $5.8B.
On our five checks Argenx scores higher: 2.4 out of 5 (weak) against 1.0 (weak).
By area, the stronger company is Argenx on future growth; Argenx on track record; Argenx on financial health.
Moderna leads on 1 of the compared lines and Argenx on 13.
Side by side
| MRNA | ARGX | |
|---|---|---|
| Size and price | ||
| Market cap | $90.4B | $59.6B |
| Share price | $223.37 | $960.04 |
| Score | ||
| Overall score (of 5) | 1.0 | 2.4 |
| Value | 0 | 0 |
| Future growth | 1 | 4 |
| Track record | 1 | 2 |
| Financial health | 2 | 5 |
| Shareholder returns | 1 | 1 |
| Valuation | ||
| P/E (TTM) | — | 33.2 |
| Forward P/E | — | 31.5 |
| Price / free cash flow | — | 193.0 |
| Price / sales | 35.8 | 10.2 |
| EV / EBITDA | — | 28.6 |
| PEG | — | — |
| DCF value vs. price | — | −72% |
| Business | ||
| Revenue | $2.5B | $5.8B |
| Net income | -$2.8B | $1.9B |
| Free cash flow | -$2.0B | $309M |
| Net margin | -110.5% | 32.2% |
| Gross margin (5-yr avg.) | 59.9% | 90.8% |
| ROIC (5-yr avg.) | 9.4% | -7.0% |
| Growth | ||
| Revenue growth (1 yr) | -39.9% | 88.6% |
| Revenue growth (5 yrs, per year) | 19.3% | 130.8% |
| EPS growth (5 yrs, per year) | — | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | $3.9B | $5.1B |
| Dividend yield | None | None |
| Shareholder yield | 0.0% | 0.0% |
| Analysts | ||
| Upside to average target | −29% | +19% |
| Consensus rating | Hold | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: MRNA TTM to September 30, 2026, ARGX TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Moderna or Argenx?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Argenx scores 2.4 out of 5 and Moderna 1.0; the table shows where each one is stronger.
Which grows faster, Moderna or Argenx?
Over five years Argenx grew revenue about 130.8% a year and Moderna about 19.3% a year.
Full Moderna analysis → Full Argenx analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.